Merck的新PAH药物Winrevair虽有希望, 但引起对高成本和出血风险的担忧。 Merck's new PAH drug, Winrevair, shows promise but raises concerns over high cost and bleeding risks.

Merck的药物Winrevair对肺动脉高血压(PAH)患者有重大好处,肺部高血压(PAH)是一种导致肺部高血压的疾病。 Merck's drug, Winrevair, has shown significant benefits for patients with pulmonary arterial hypertension (PAH), a condition causing high blood pressure in the lungs. 在一项后期研究中,发现它能够减少疾病恶化、肺移植或死亡的风险。 In a late-stage study, it was found to reduce the risk of disease worsening, lung transplantation, or death. Winrevair是针对一种叫做活性素的特定蛋白质的首例治疗, Approved in the US and other countries, Winrevair is the first treatment targeting a specific protein called activin. 尽管药物有效,但每年价格约为238,000美元,引起了人们对潜在出血风险的关切。 Despite its effectiveness, the drug, priced at about $238,000 annually, has raised concerns over potential bleeding risks.